The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Influential Lancet Article on HCQ Retracted

Influential Lancet Article on HCQ Retracted

June 5, 2020 • By Michael Erman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it.

You Might Also Like
  • WHO Expects HCQ Safety Findings by Mid-June
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • U.K. Healthcare Workers Begin COVID-19 HCQ Trial

The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well as implications of the study published in British medical journal the Lancet last month.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The three authors said Surgisphere, the company that provided the data, would not transfer the full dataset for an independent review and that they “can no longer vouch for the veracity of the primary data sources.”

The fourth author of the study, Dr. Sapan Desai, the CEO of Surgisphere, declined to comment on the retraction.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The observational study published in the Lancet on May 22 looked at 96,000 hospitalized COVID-19 patients, some treated with the decades-old malaria drug. It claimed that those treated with HCQ or the related chloroquine had higher risk of death and heart rhythm problems than patients who were not given the medicines.

Several clinical trials were put on hold after the study was published. The World Health Organization, which paused HCQ trials after The Lancet study was released, said it was ready to resume trials.

Many scientists voiced concern about the study. Nearly 150 doctors signed an open letter to The Lancet last week calling the article’s conclusions into question and asking to make public the peer review comments that preceded publication.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“I did not do enough to ensure that the data source was appropriate for this use,” the study’s lead author, Harvard Medical School Professor Mandeep Mehra, says in a statement. “For that, and for all the disruptions—oth directly and indirectly—I am truly sorry.”

Surgisphere was not immediately available for comment.

The Lancet in a statement says, “There are many outstanding questions about Surgisphere and the data that were allegedly included in this study.”


(Reporting by Michael Erman and Peter Henderson. Editing by Tom Brown and Leslie Adler.)

Reference

  1. Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet. 2020 May 22.

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, HCQ, Hydroxychloroquine (HCQ), Research

You Might Also Like:
  • WHO Expects HCQ Safety Findings by Mid-June
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • U.K. Healthcare Workers Begin COVID-19 HCQ Trial
  • HCQ Prolongs QT Interval in Patients with COVID-19

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)